# Albireo Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/albireo-pharma

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.albireopharma.com
- Total disclosed funding: $40M
- Latest round: Series A (May 7, 2008)
- Investors on record: 4

## About

Albireo Pharma, Inc. is a US-based biopharmaceutical company focused on developing innovative medicines for rare diseases and gastrointestinal conditions, aiming to improve patient outcomes through specialized therapies.Albireo Pharma, Inc. is dedicated to developing treatments for rare gastrointestinal diseases. Founded in 2008, the company is headquartered in Boston, US. It emerged from a merger between Albireo Limited and Biodel Inc. in May 2016, which resulted in a shift in its operational focus. The company has secured recent investment totaling USD 952.00 mn from Ipsen, with a total amount raised also at USD 952.00 mn through five deals. The current CEO is Gert Borg, while the founder is Jan Mattsson, who has a history of founding other companies.Albireo Pharma, Inc. specializes in innovative drug development for rare gastrointestinal diseases. Their product offerings are aimed at addressing unmet medical needs and include treatments designed to improve health outcomes significantly. The company focuses on developing therapies that target specific conditions, ensuring that patients receive effective solutions for their health challenges.In 2021, Albireo Pharma, Inc. reported a revenue of USD 40.58 mn, with an EBITDA of USD -123.21 mn. The revenue is primarily derived from pharmaceutical product sales to healthcare providers and institutions, demonstrating the company's operational scale in providing specialized treatments across global markets.Albireo Pharma, Inc. is strategically planning to expand its product portfolio with new therapies targeting rare gastrointestinal conditions, leveraging recent investments for research and development. The company is also exploring opportunities to enter new geographical markets, with a focus on regions such as Europe and Asia-Pacific by 2025. The funding received will support these initiatives and enhance their capabilities in delivering specialized healthcare solutions.

## Funding rounds

- Series A, May 7, 2008, $40M — TVM Capital Life Science, Scottish Widows Investment Partnership, Phase4 Partners, TPG Biotech

## Investors

- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A
- Scottish Widows Investment Partnership (https://capitalatlas.ai/funds/scottish-widows-investment-partnership) — Series A
- Phase4 Partners (https://capitalatlas.ai/funds/phase4-partners) — Series A
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series A